HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8(+) T and NK cells: a novel therapeutic tumour vaccine

BACKGROUND: CD8(+) T cell-mediated adaptive cellular immunity and natural killer (NK) cell-mediated innate immunity both play important roles in tumour immunity. This study aimed to develop therapeutic tumour vaccines based on double-activation of CD8(+) T and NK cells. METHODS: The immune Epitope d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hematol Oncol
Autors principals: Yu, Zhaojin, Liu, Wensi, He, Ying, Sun, Mingli, Yu, Jiankun, Jiao, Xue, Han, Qiang, Tang, Haichao, Zhang, Bing, Xian, Yunkai, Qi, Jing, Gong, Jing, Xin, Wang, Shi, Gang, Shan, Fengping, Zhang, Rui, Li, Jianping, Wei, Minjie
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8082934/
https://ncbi.nlm.nih.gov/pubmed/33910591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-021-01081-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars